Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Laura MillaresGrupo Colaborativo en Cáncer de Pulmón CIBERES- CIBERONC- SEPAR - Plataforma Biobanco Pulmonar

Abstract

Non-small cell lung cancer (NSCLC) patients diagnosed in early stage and surgically-treated have five-year mortality rate >20%. The identification of biomarkers able to predict progression and death may help to identify patients needing closer follow-up. A retrospective cohort of early-stage surgically-treated NSCLC patients enrolled in the International Association for the Study of Lung Cancer (IASLC) Staging Project was created, and tissue Microarrays (TMAs) were constructed with tumor and non-tumor lung tissue. Pentose phosphate pathway (PPP) proteins (transketolase [TKT] and transketolase-like 1 [TKTL1]), inflammatory markers (cyclooxygenase-2 [COX-2], tumor necrosis factor alpha [TNF-α], interleukin 1 beta [IL1β], nuclear factor kappa-light-chain-enhancer of activated B cells [NFκB]-p65 and antigen Ki-67), and programmed death-ligand 1 (PDL1) were measured by immunohistochemistry. NSCLC patients with adenocarcinoma (ADC) or squamous cell carcinoma (SCC) were included in the study (n = 199). TKT and TKTL1 were significantly higher in ADC than in non-tumor tissue (p < 0.001). Higher values were also observed in NSCLC for all the inflammatory markers, with figures >30% above those of non-tumor tissue (p < 0.001). PDL1 analysi...Continue Reading

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Nov 19, 2004·Nature·Neil A BhowmickHarold L Moses
Oct 27, 2006·The New England Journal of Medicine·UNKNOWN International Early Lung Cancer Action Program InvestigatorsOlli S Miettinen
Feb 13, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M KrockenbergerU Kammerer
Aug 10, 2007·Journal of the National Cancer Institute·Masahiro SeikeCurtis C Harris
Aug 14, 2008·Diagnostic Pathology·Holger SchultzTorsten Goldmann
Sep 26, 2008·The New England Journal of Medicine·Roy S HerbstScott M Lippman
Dec 10, 2008·International Journal of Cancer. Journal International Du Cancer·Xiaojun XuMartin Löchelt
May 23, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Dorothy J GirouxUNKNOWN International Association for the Study of Lung Cancer International Staging Committee
Aug 3, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P BoyleJ F R Robertson
Nov 26, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Roy M BremnesLill-Tove Busund
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jan 3, 2012·Seminars in Cancer Biology·Frances R Balkwill, Alberto Mantovani
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Mar 24, 2012·Cancer Cell·Patrick S Ward, Craig B Thompson
Jul 24, 2012·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Martin GrimmJoachim Polligkeit
Dec 4, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shaun DalyJeffrey A Borgia
Jul 11, 2013·Archivos de bronconeumología·Julio Sánchez de Cos EscuínAlberto Saura Vinuesa
Sep 21, 2013·Nature Immunology·Thomas F GajewskiYang-Xin Fu
Nov 10, 2013·Nature Medicine·Daniela F Quail, Johanna A Joyce
Jul 20, 2014·Trends in Biochemical Sciences·Krushna C Patra, Nissim Hay
Dec 2, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ramón Rami-PortaUNKNOWN International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and
Apr 22, 2015·Clinical & Experimental Metastasis·Carmela RicciardelliMartin K Oehler
Sep 12, 2015·Expert Opinion on Biological Therapy·Francesco PassigliaAntonio Russo
Nov 20, 2015·American Journal of Respiratory and Critical Care Medicine·Emma M ConwayKevin L Bennewith
Jan 15, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Particip
Feb 26, 2016·Virchows Archiv : an International Journal of Pathology·Marius IliePaul Hofman
Jul 9, 2016·Oncotarget·Santiago Diaz-MoralliMarta Cascante
Jan 4, 2017·Oncotarget·Míriam Tarrado-CastellarnauMarta Cascante

❮ Previous
Next ❯

Citations

Oct 9, 2020·Signal Transduction and Targeted Therapy·Xiaoling SongYingbin Liu
Feb 23, 2021·Expert Review of Proteomics·Hanie AbolfathiSeyed Ali Nojoumi
Mar 4, 2021·Future Oncology·Asrar AlamSujata Pathak
Feb 24, 2021·Cellular & Molecular Biology Letters·Yu LiuLiangcheng Zheng
Jun 23, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hou-Qun YingXue-Xin Cheng
Sep 4, 2021·Scientific Reports·Zhao YangMan Ki Kwok
Jan 29, 2022·Biomarker Research·Jun Zhang, Nirmal Veeramachaneni

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Related Papers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Kai-Yu HanJia-Ning Li
International Journal of Radiation Oncology, Biology, Physics
Yong Bae KimTchan Kyu Park
Cancer Biomarkers : Section a of Disease Markers
Yan SongGuoping He
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Long-Xiao WeiMeng-Hui Yuan
© 2022 Meta ULC. All rights reserved